Physician profile
Gerald E Morris
NPI 1619269875
$9,953.04
in general payments reported to CMS, 2019-2025
42 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,846 · 2020: $2,226 · 2021: $2,203 · 2022: $1,543 · 2023: $835 · 2024: $798 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.35 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,194.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,046.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $831.66 | 2019-2025 | Mounjaro, Kisunla |
| Amgen INC. | $680.83 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $571.55 | 2019-2023 | Trintellix |
| Abbvie INC. | $561.90 | 2020-2024 | |
| Glaxosmithkline, LLC. | $553.71 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.92 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $421.94 | 2019-2025 | |
| Merz North America, INC. | $409.00 | 2020-2024 | |
| Pfizer INC. | $408.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.24 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $327.34 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $311.95 | 2021-2023 | Ajovy, Austedo Xr |
| Merck Sharp & Dohme LLC | $271.93 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.